Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 3 1Phase 1/2 1

Status

Active not recruiting 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Recurrence 4Immunoglobulin Light-chain Amyloidosis 3Burkitt Lymphoma 3Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Mastocytosis, Systemic 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Plasma Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Leukemia, Biphenotypic, Acute 1Leukemia 1Intraocular Lymphoma 1Hypersensitivity 1Hematologic Neoplasms 1

Interventions

Dexamethasone 7Calcium Dobesilate 5Filgrastim 4Cyclophosphamide 4miridesap 3ixazomib 3dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Peripheral Blood Stem Cell Transplantation 3Bortezomib 3venetoclax 2Tacrolimus 2Methylprednisolone 2Amifostine 2sargramostim 1pyroxamide 1pomalidomide 1nelarabine 1melflufen 1isatuximab 1fludarabine phosphate 1daratumumab 1X-Rays 1Topotecan 1Tetradecanoylphorbol Acetate 1Technetium Tc 99m Pyrophosphate 1Technetium 1Sunitinib 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Immunoglobulin Light-chain Amyloidosis × dexamethasone acetate × Clear all
NCT04847453 2026-05-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03283917 2026-02-27

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
21 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04754945 2026-02-18

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

Emory University

Phase 1 Active not recruiting
11 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡